DUBLIN, Aug 6, 2021 – (BUSINESS WIRE) – Added the Veterinary Vaccines Global Market Report 2021: COVID-19 Impact and Recovery to 2030 ResearchAndMarkets.com to offer.
The main players in the veterinary vaccine market are Boehringer Ingelheim GmbH, Merck Animal Health, Zoetis Inc., Eli Lilly and Company, and Bayer AG (Bayer Animal Health).
The global veterinary vaccine market is expected to grow from $ 7 billion in 2020 to $ 7.73 billion in 2021, with an average annual growth rate (CAGR) of 10.4%.
The growth is mainly due to companies reorganizing their operations and recovering from the effects of COVID-19, which previously resulted in restrictive containment measures involving social distancing, remote working and the closure of commercial activities that created operational challenges.
The market is expected to reach $ 10.18 billion at a CAGR of 7.1% in 2025.
The veterinary vaccines market consists of the sale of vaccines and related services for the treatment and prevention of animal diseases. These veterinary vaccines reduce animal suffering and the transmission of microorganisms in the animal population. Veterinary vaccines are used to boost animal immunity by improving animal health, which also prevents the transmission of diseases from animals to humans. The veterinary vaccine industry includes companies that make veterinary vaccines such as livestock vaccines and pet vaccines.
Companies in the veterinary vaccine market are increasingly looking for strategic partnerships and collaborations to open up new regions and share research and development projects. For example, in 2020 the Pirbright Institute, a UK animal disease research institute, partnered with ECO Animal Health, a UK pharmaceutical company, and the Vaccine Group (TVG) to develop vaccines against Porcine Respiratory and Reproductive Syndrome Virus (PRRSV).
The Vaccines Group is a biotechnology company that develops animal vaccines and is based in Plymouth, UK. MSD Animal Health, a division of Merck & Co headquartered in the USA, also entered into a strategic partnership with Vinovo. This partnership will help MSD Animal Health combine its unique broad line of vaccine products and Vinovo’s vaccine delivery system with the vaccination process to improve bird welfare and reduce vaccine reactions. In addition, Wageningen Bio-Veterinary Research has entered into a strategic alliance with Ceva, headquartered in Switzerland, to improve its research on the global threat from emerging and recurring animal diseases.
The story goes on
High storage costs are holding back the growth of the veterinary vaccine market. Improper storage conditions and delays in shipping can cause vaccines to lose their desired immune properties. For example, vaccines can biodegrade in transit if they are not transported within the required temperature limits.
Thus, special care is required in transporting the vaccines to maintain the effectiveness of the vaccines, which increases the storage and transportation costs for the vaccines. According to a report released by the National Institute of Standards and Technology (NIST), about 35% of vaccines lost their effectiveness during shipping because they were stored at abnormal temperatures. Therefore, high vaccine storage costs are expected to result in additional costs for the manufacturing companies and limit the growth of the market.
The veterinary vaccine market is regulated by agencies such as the European Medical Agency and the US Center for Veterinary Biologics. For example, manufacturers of veterinary vaccines in Europe must comply with the European technical requirements and the European Pharmacopoeia (Ph. Eur.) Listed in Appendix 1, Title II of Directive 2001/82 / EC, as amended by Directive 2009/9 / EC.
The increase in the number of animals suffering from a range of diseases increases the demand for vaccines to prevent and treat such diseases, fueling the veterinary vaccine market, according to estimates from the Agency for Animal and Phytosanitary report, a total of 3,289 in England new incidents of tuberculosis were noted.
However, the disease can be treated with specific antibiotics that kill the TB bacteria. This rising animal disease prevalence is expected to drive the veterinary vaccine market over the forecast period.
Key topics covered:
1. Summary
2. Market characteristics for veterinary vaccines
3. Veterinary Vaccine Market Trends and Strategies
4. Effects of COVID-19 on animal vaccines
5. Veterinary Vaccines Market Size and Growth
5.1. Global Historic Veterinary Vaccines Market, 2015-2020, $ Billion
5.1.1. Drivers of the market
5.1.2. Restrictions in the market
5.2. Global Veterinary Vaccine Market, 2020-2025F, 2030F, Billion US Dollars
5.2.1. Drivers of the market
5.2.2. Restrictions in the market
6. Veterinary Vaccines Market Segmentation
6.1. Global Veterinary Vaccines Market, Segmentation By Application, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars
6.2. Global Veterinary Vaccines Market, Segmentation By Vaccine Type, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars
-
Live attenuated vaccines
-
Inactivated vaccines
-
Toxoid vaccines
-
Recombinant Vaccines
-
Other
6.3. Global Veterinary Vaccines Market, Segmentation By Disease Type, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars
7. Regional and country analysis of the veterinary vaccines market
7.1. Global Veterinary Vaccines Market Split by Region, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars
7.2. Global Veterinary Vaccines Market Split by Country, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars
Mentioned companies
-
Boehringer Ingelheim GmbH
-
Merck Animal Health
-
Zoetis Inc.
-
Eli Lilly and Company
-
Bayer AG (Bayer Animal Health)
-
Some animal health
-
Virbac
-
Biovac
-
Zoetis Animal Health
-
Hester Biosciences Ltd
-
Elanco
-
Phibro Animal Health Corp.
-
Some animal health
-
Biovac
-
Biogenesis New SA
-
Hester
-
Neogen Corporation
-
ImmuCell Corporation
-
Indian Immunologicals Ltd
-
Heska Corp.
-
Pfizer
-
Sanofi SA
-
Vetoquinol
-
Hipra
-
Nexvet
Please visit https://www.researchandmarkets.com/r/iwt18w for more information on this report
View source version on businesswire.com: https://www.businesswire.com/news/home/20210806005217/de/
contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For EST office hours, call 1-917-300-0470
For US / CAN toll free call 1-800-526-8630
For GMT office hours, call + 353-1-416-8900. at
